Technology | October 11, 2012

Boston Scientific Launches Victory Guidewire For Crossing Resistant Peripheral Lesions

Victory guidewires are designed to facilitate crossing of resistant lesions

Boston Scientific Victory Crosswire Peripheral Artery Disease

October 11, 2012 — Boston Scientific Corporation has begun the U.S. and European launch of its Victory guidewire, designed to facilitate crossing of resistant lesions and the placement and exchange of balloon catheters or other interventional devices within the peripheral vasculature.  The company expects to launch the product in other international markets later this year and in 2013, subject to regulatory approvals.

An estimated 17.6 million Americans suffer from peripheral artery disease, which is characterized by blockage or narrowing in vessels of the peripheral vasculature, frequently associated with high rates of morbidity and mortality.  Critical limb ischemia (CLI) is a serious condition affecting an increasing number of patients worldwide.  CLI patients have multi-vessel disease and challenging lesions, which, if left untreated, can lead to limb loss.  In the United States, an estimated 25 percent of patients with peripheral artery disease will require amputation within one year of onset of CLI.  Saving limbs through surgery or endovascular techniques improves the quality of life for patients.

"Resistant lesions can be a challenge and I often need various tools to access, cross and treat these types of lesions," said Derek Mittleider, M.D., interventional radiologist, director, vascular and interventional radiology, Spectrum Medical Group.  "The Victory wire's high gram-load options and excellent torque-ability give me the extra push and steer-ability I need to get through these resistant lesions more easily, making these cases less challenging."

The Victory guidewires feature a broad matrix of high gram-load tip options ranging from 12 grams to 30 grams, designed to cross-resistant lesions.  A unique stainless steel core technology enables this wire to have superior torque for optimal steering and control.  Hydrophilic coating provides enhanced lubricity to facilitate crossing resistant lesions.  The Victory guidewires come in both 0.014-inch and 0.018-inch diameters with four different gram-load options offering clinical versatility and a range of pushability.

"Physicians treating CLI patients typically require a variety of treatment options. Boston Scientific is committed to offering a wide variety of crossing solutions," said Jeff Mirviss, president of the Boston Scientific Peripheral Interventions Division.  "Victory guidewires complement our already broad portfolio of crossing solutions, inclusive of our market-leading angioplasty balloons, Rubicon Support Catheter and the TruePath CTO device. The Victory guidewires offer another option to cross these highly resistant lesions and potentially avoid the need for amputation."

For more information: www.bostonscientific.com

 

 

Related Content

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD)| September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Overlay Init